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Alzheimer’s disease (AD) is a neurodegenerative disorder that impairs mainly the memory and cognitive function in
elderly. Extracellular beta amyloid deposition and intracellular tau hyperphosphorylation are the two pathological
events that are thought to cause neuronal dysfunction in AD. Since the detailed mechanisms that underlie the
pathogenesis of AD are still not clear, the current treatments are those drugs that can alleviate the symptoms of AD
patients. Recent studies have indicated that these symptom-reliving drugs also have the ability of regulating
amyloid precursor protein processing and tau phosphorylation. Thus the pharmacological mechanism of these
drugs may be too simply-evaluated. This review summarizes the current status of AD therapy and some potential
preclinical considerations that target beta amyloid and tau protein are also discussed.
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Alzheimer’s disease (AD) is a progressive neurodegenera-
tive disease characterized clinically by insidious onset of
memory and cognition impairment, emergence of psychi-
atric symptoms and behavioral disorder, and impairment
of activities of daily living. It is the most frequent form of
dementia found in the elderly. It is estimated that the
prevalence of AD over the age of 85 may be as high as
25~50%, and AD is increasingly being recognized as one
of the most important medical problems in the elderly.
With the increasing number of elderly and growing of life
expansion, more people will be suffered from AD, thus
give a great economic burden to the families, the care-
givers and the whole society. Since detailed molecular
mechanisms underline the pathophysiology of AD are still
remained to be clarified, currently available drug therapies
for AD consist primarily of cholinesterase inhibitors
(donepezil, galantamine, rivastigmine, Huperzine A) and
an N-methyl-D-aspartate receptor antagonist (memantine)
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reproduction in any medium, provided the or(FDA) and some neuroprotective agents. Although these
drugs did alleviate some of the psychological and behav-
ioral symptoms of AD patients, effective pharmacological
interventions for prevention and treatment of AD, that is,
the disease-modifying therapies, are lacking.
During the past decade, many hypotheses have been
put forward for AD pathogenesis. Among them, the β-
amyloid (Aβ) cascade and the tau hyperphosphorylation
are the theories that have widely been accepted. Thus
the disease-modifying therapies focus mainly on the
agents that will decrease Aβ content and tau hyperpho-
sphorylation. Here we review the potential disease-
modifying therapies and some compounds that are
currently undergoing preclinical and clinical evaluations.Cholinesterase inhibitors
Post-mortem studies indicated the reduced choline up-
take, acetylcholine (ACh) release and progressive loss of
cholinergic neurons in AD brain. This “cholinergic defi-
cient hypothesis” claims that the symptoms of AD is
caused by decreased acetylcholine in the presynapse, thus
increasing acetylcholine by inhibiting its degradation
should improve the memory and cognition impairment in
AD. Since 1993, the FDA approved four cholinesterase
inhibitors for treatment of mild to moderate AD, thel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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galantamine (2001). But tacrine was later abandoned
because of its hepatotoxicity, gastrointestinal adverse reac-
tions, poor oral bioavailability and frequent dosing
requirements. Multi-center randomized double-blind clin-
ical trails indicated that donepezil and galantamine are
effective in improving and maintaining cognitive and glo-
bal function and activities of daily life as compared with
control group. And the side effects with donepezil and
galantamine are usually mild and taper with continued use
and can be minimized by taking with food. Butylcholines-
terase has also been found to degrade ACh in healthy and
AD-affected brains and is an additional target for the
treatment of AD. Rivastigmine is an inhibitor of both
AChE and butylcholinesterase, and clinical trails showed
that it was effective in improving cognition and functional
impairment without apparent side effects in AD patients
compared with placebo. Besides the above mentioned
effects, donepezil and rivastigmine can also affect amyloid
precursor protein processing, which means that the
“cholinergic deficient hypothesis” may be too simple and
that still other mechanisms may exit besides restoring Ach
balance. The cholinergic system may play a role in the
production of two proteins responsible for neurotoxicity
in AD: Aβ and tau. Except the drugs approved by the
FDA, still many other cholinesterase inhibitors are under
clinical trials. For example, phenserine treatments
increased cognition and regional cerebral metabolic rate
for glucose in AD patients. Clinical trial with Dimebon, a
cholinesterase inhibitor and also a NMDA-antagonist,
showed improved cognitive and self-service functions
while diminishing the psychopathic symptoms in AD
patients. Huperzine A, a Chinese herb with reversibly and
selectively acetylcholinesterase inhibition activity, dis-
played good pharmacokinetics with a rapid absorption
and a wide distribution in the body at a low to moderate
rate of elimination. Clinical trials have shown its cognitive
enhancement in AD at a dose of 0.4 mg and seems to be a
potential treatment option for AD. The development of
the multimodal drug, ladostigil, combined neuroprotective
effects with monoamine oxidase (MAO) -A and -B and
cholinesterase inhibitory activities in a single molecule,
was tested in Phase II clinical trial intended for AD, and
the results are unpublished yet. Donepezil was first devel-
oped for mild to moderate (5~10 mg/d) AD patients, but
larger dose (23 mg/d) was recently approved in the U.S.
for treatment of moderate to severe AD. The good safety
and predictable tolerability profile in a phase 3 trial for
donepezil 23 mg/d supports its favorable risk/benefit ratio
in patients with advanced AD [1]. Rivastigmine is effective
in improving the cognitive and global functioning in AD
patients, but the incidence of nausea and vomiting make it
difficult to maintain high therapeutic doses in clinical
practice. By delivering the drug through the skin anddirectly into the bloodstream, transdermal patches
resulted in reduced rates of nausea and vomiting com-
pared with oral ChEIs and represents a next generation of
acetylcholinesterase treatments. In a four week prospect-
ive, multicenter, observational study on transdermal rivas-
tigmine in Germany, 11.7% of patients had adverse evens,
mainly affecting the skin or the gastrointestinal tract. Only
a minor proportion of patients discontinued therapy due
to adverse evens. With rivastigmine treatment, the per-
centage of patients taking psychotropic comedication
decreased and these results were in line with data from
controlled clinical trials. Still other candidates are being
tested and the data are to be published.
Aβ-targeting strategies
One of the hallmarks of AD is the presence of senile pla-
ques in the hippocampus, which are primarily formed
from the extracellular deposition of Aβ, a 40-42(3)
amino acid polypeptide. The Aβ is deprived from a large
transmembrane protein, the amyloid precursor protein
(APP) by sequential proteolysis of two proteases, the β-
and γ-secretase, at the N- and C-terminus of the Aβ se-
quence respectively. Alternatively, APP can also be pro-
cessed by α-secretase within the Aβ sequence and thus
not only preclude the formation of Aβ peptide but also
generate a soluble neurotrophic sAPPα. Many experi-
ments indicated that Aβ is a neurotoxin; it aggregates
and forms deposits that finally lead to neuronal dysfunc-
tion. The pathological accumulation of Aβ in the brain
leads to oxidative stress, neuronal destruction and finally
the clinical symptoms of AD. Following this hypothesis,
secondary prevention of AD can be made by: decreasing
the production of Aβ, stimulation of clearance of Aβ
formed or prevention of aggregation of Aβ into amyloid
plaques (Figure 1). The corresponding targets are also
indicated in the figure.
β-secretase inhibitors
The therapeutic potential of β-secretase (also named β-
site APP cleaving enzyme, BACE1) inhibitor has been sug-
gested by several studies. BACE-knockout mice develop
normally, showed no consistent phenotypic differences
from their wild-type littermates and produced much less
Aβ from APP. Lateral ventricles injection of BACE inhibi-
tor led to a significant dose- and time-dependent lowering
of brain Aβ40 and Aβ42, a robust decreased sAPPβ and
an increased sAPPα secretion. While injection of another
inhibitor KMI-429 into the hippocampus of APP trans-
genic mice reduced Aβ production. Although the data
were positive both in animal and cells levels, the drugs
used are mostly small peptides and are not appropriate for
clinical application with their ability of penetrating the
blood–brain barrier are susceptible. Development of new
drugs especially small molecules which can penetrate the
Figure 1 The Aβ-targeting strategies based on the Aβ cascade hypothesis. The processing of APP and the production, degradation of Aβ
are illustrated and the therapeutic potential of targets are indicated with vertical arrows marked by alphabet: A, α-secretase activators; B,
β-secretase inhibitors; C, γ-secretase inhibitors/modulators; D, immunotherapy; E, Aβ-aggregation inhibitors; F, Aβ-degradation activators.
Modified and reproduced with permission from Yang et al. (2012) and see reference [2] for further details.
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mice, oral administration of non-peptidic BACE1 inhibi-
tor, GSK188909, results in a significant reduction in the
level of Aβ40 and Aβ42 in the brain. PMS777, a new cho-
linesterase inhibitor with anti-PAF activity, could decrease
sAPPα secretion and Aβ42 release in SH-SY5YAPP695 cells
and PC12 cells although its effect on BACE1 is not clear
[3]. This neuroprotection in increasing the memory and
cognitive ability in demented mice induced by scopolam-
ine as evidenced by Morris water-maze test suggested its
therapeutic potential. Inhibition of APP dimerization by
small molecules resulted in reduction in Aβ levels as mea-
sured by ELISA. This effect is accompanied by lowered
sAPPβ levels, suggesting that blocking the dimerization
can prevent the cleavage by β-secretase in the amyloido-
genic processing of APP. Thus APP dimerization inhib-
ition may be a viable means of reducing Aβ production
[4]. Recently the mechanisms of tight regulation of BACE1
from transcriptional, post-transcriptional and post-
translational levels are increasingly illustrated and may
provide new insights for clinical application in the near
future [5].
γ-secretase inhibitors/modulators
Treatment of AD mice/rats with γ-secretase inhibitors
DAPT resulted in decreased Aβ levels in plasma and
cerebrospinal fluid (CSF). The data is also positive in
other γ-secretase inhibitors like BMS-299897 and MRK-
560. LY450139 dihydrate, another γ-secretase inhibitor,
was studied in a randomized, controlled trial of 70
patients with mild to moderate Alzheimer disease. Andthe results indicated that it decreased 38% plasma Aβ40
and 4.5% CSF Aβ40, and the treatment was well toler-
ated. Recruitment of double blind placebo controlled
Phase III study of tarenflurbil in patients with mild AD
showed no benefit on cognitive or functional outcomes
and the program was thus discontinued following this
disappointing. Notch, which is necessary for growth and
development, is also a substrate of γ-secretase. Notch
related side effects of γ-secretase inhibition (e.g. severe
gastrointestinal and haemopoetic side effects, neurode-
generation) have been hampering the development of
clinically useful γ-secretase inhibitors so far. Thus the
drug development is now focusing on the development
of γ-secretase modulators, with the purpose of shifting
the γ-secretase cutting point to produce shorter, non-
toxic Aβ fragments. Some non-steroidal anti-inflamma-
tory drugs (NSAIDs) such as tarenflurbil, is a promising
candidate. A phase II trial with tarenflurbil with mild to
moderate AD showed a significant improvement in pri-
mary outcome of global functioning and activities of
daily living, compared to placebo and a positive trend
towards improved cognition. Although it reduced
amyloid-β deposition in the PDAPP transgenic mouse
after 5 months of administration and have a statistically
significant reduction in newly synthesized Aβ in human
volunteers, the results in Phase III trials demonstrated
that patients who were treated with it displayed an
increased deterioration in cognition and activities of
daily living compared to placebo-treated controls and it
was discontinued. With its very complex mode of action,
it can’t be excluded that this compound-mediated
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Notch signaling [6].
α-secretase activators/modulators
Since α-secretase and β-secretase compete for the same
substrate of APP, upregulation of α-secretase activity may
decrease the amount of APP available for β-secretase, and
thus decrease Aβ secretion and have therapeutic potential.
Many studies had indicated that members of the adamaly-
sin family of proteins, mainly ADAM 10, ADAM 17 and
ADAM 9, fulfill some of the criteria required of α-secretase.
Overexpression of ADAM10 in transgenic mice showed
not only less amyloid deposition in the hippocampus and
lower Aβ levels in brain homogenate when compared with
APP monotransgenic mice, but also improved neurological
function as evaluated by long term potentiation (LTP) and
the Morris water-maze test [7]. Many studies indicated that
the currently effective drug for AD all can increase α-
secretase activities [8]. Our previous study showed that
protein kinase C (PKC) activator TPPB could increase α-
secretase activity and decrease Aβ secretion [9]. SIRT1
could activate the gene code for α-secretase ADAM10
and then suppress Aβ production in AD transgenic mice
[10]. Deprenyl, a neuroprotective agent used to slow AD
progress, was shown to increase α-secretase activity by
promoting ADAM10 and PKCα/ε translocation [11]. As
epigenetics involvement in AD pathogenesis is increa-
singly illustrated [12], compounds with PKC activation
and HDAC inhibition properties may offer a new ap-
proach to therapies that exhibit disease-modifying effects
in the treatment of AD, as opposed to symptomatic relief
only [13]. This implies that stimulating α-secretase
through several pathways may have therapeutic potential
and the work is going on, but no clinical data available
at present.
M1 muscarinic agonists
M1 muscarinic receptors play a role in an apparent link-
age of three major hallmarks of AD: Aβ peptide; tau
hyperphosphorylation and loss of cholinergic function
conductive to cognitive impairments. It was discussed
here because it can also regulate secretase activities. Acti-
vation of M1 mAChRs with these agonists leads to
enhanced secretion of sAPPα, (via α-secretase activation),
to decreased Aβ (via γ-secretase inhibition), and the inhib-
ition of Aβ- and/or oxidative stress-induced cell death.
Talsaclidine is a functionally selective muscarinic M1
agonist that stimulates non-amyloidogenic α-secretase
processing in vitro. In a double-blind, placebo-controlled,
and randomized clinical study in AD patients, treatment
with talsaclidine decreased CSF Aβ about 20% as com-
pared with the baseline, suggesting its therapeutic poten-
tial. AF102B, another M1 agonist, also decreased CSF Aβ
of AD patients, and clinical trials will determine if AF267Bmay become an important therapy in AD. In vitro studies
indicated that these M1 agonists may act through decreas-
ing γ-secretase and increasing α-secretase activities that
finally decreased Aβ secretion. And it also decreased tau-
phosphorylation.
Aβ-aggregation inhibitors
The neurotoxic effect of Aβ has been documented on
numerous occasions and thus decreasing its neuroto-
xicity or inhibiting its aggregation may have therapeutic
potentials. The first drug was a β-sheet breaker iAβ5p,
which showed that intrahippocampal injection of it
resulted in improved spatial memory and decreased amyl-
oid plaque deposits. Tramiprosate (3APS, Alzhemed) is
a compound that binds to soluble Aβ and inhibits the
formation of neurotoxic aggregates that lead to amyloid
plaque deposition in the brain. Phase II clinical trial
with mild to moderate AD patients showed that it dose-
dependently reduced CSF Aβ42 levels after 3 months of
treatment, but had no significant effect on CSF40, tau
and psychometric scores between groups. Disappoint-
ing results of the US phase III trial in the year 2007
have led to discontinuation of the European phase III
trial. Thus, the trials of other antifibrilization agents are
planned.
Immunotherapy
Both active (vaccination) and passive (monoclonal anti-
bodies) immunization are studied in AD patients after
promising data from in vitro experiments and animal
studies. Active immunization against Aβ42 in transgenic
mice resulted in decreased plaques and improved cogni-
tive function as tested by Morris water maze trials.
These exciting results led to clinical vaccination trials in
patients with AD. A randomized, double-blind, placebo-
controlled, phase II clinical trial with the synthetic Aβ
peptide AN1792/QS-21 in patients with mild to moder-
ate AD was initiated, but the trial was later discontinued
because of approximately 6% of the immunized AD
patients (18/300) developed meningoencephalitis [14].
And the study also indicated a dissociation between
brain volume loss and cognitive function in AN1792/
QS-21 antibody responders as measured by MRI scan-
ning. Patients treated with AN1792/QS-21 showed
decreased plaque pathology and only patients with men-
ingoencephalitis showed increased T-cell activation. It
was thus speculated that T-cell response may be neces-
sary for development of meningoencephalitis. A recent
completed clinical trial with Aβ42 immunization indi-
cated that although immunization with Aβ(42) resulted
in clearance of amyloid plaques in patients with Alzhei-
mer's disease, this clearance did not prevent progressive
neurodegeneration [15]. Alternatively, new modified vac-
cines which contains the antibody epitope(s) but lacks
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ranted. To achieve this, a novel peptide-carrier protein
using an amino-terminal fragment of Aβ has been deve-
loped to avoid potentially harmful T-cell responses,
while maintaining a similar antibody response to that of
AN1792. The initial data are promising and the trials are
going on. Passive immunotherapy in AD patients with
repeated intravenous administration of human immuno-
globulin against Aβ peptide resulted in stopped cognitive
decline and slight improvement in functional scores and
phase I and II clinical trials with LY2062430 are also
being investigated. A phase II, multicenter, randomized,
double-blind, placebo-controlled clinical trials of bapi-
neuzumab decreased total and phosphorylated tau levels
in CSF without affecting Aβ level with some patients
developed transient cerebral vasogenic edema [16,17].
To date, although most of immunotherapy showed cog-
nitive function improvement and beta amyloid load
reduction by PET study, the adverse events are still the
question to be solved.
Aβ-degrading enzymes
Recent studies have indicated that Aβ peptide could be
degraded by a kind of protease called Aβ degrading
enzyme, rather than being cleared from the vascular sys-
tem by the so-called “vascular pathway”. There is a kin-
etic equilibrium between Aβ production, degradation
and transportation within the brain and transport out of
the brain. The following proteinases have the abilities of
degradating Aβ peptide: neprilysin (NEP), insulin-
degrading enzyme (IDE), plasmin, endothelin converting
enzyme (ECE) 1 and 2 and angiotensin-converting en-
zyme (ACE). All these proteinase can degrade the Aβ
peptide at different amino acid residues within the Aβ
sequence. NEP inhibitor injection and/or NEP knockout
mice showed decreased Aβ degradation and cognitive
activities declining, while overexpression of NEP resulted
in improved spatial memory and decreased Aβ levels.
Researchers have observed decreased NEP activities with
increasing age and thus besides decreasing Aβ produc-
tion, increasing Aβ degradation may also have thera-
peutic potential. Gene transfer studies have generated
positive data in transgenic mice and neuroscientist are
seeking for small molecules that can stimulate NEP
activities. Studies have showed that APP intracellular do-
main (AICD) could upregulate NEP transcription and
increase Aβ degradation [18]. Imatinib, a tyrosine kinase
inhibitor, was shown to elevate AICD in H4 human neu-
roglioma cells, and this was accompanied by concomi-
tant increases of NEP protein, mRNA levels, and activity
[19]. Valproic acid, a widely used drug in the treatment
of epilepsy, was capable of up-regulating NEP expression
and activity in human neuroblastoma SH-SY5Y cell lines.
Injections of valproic acid to rats resulted in upregulationof expression and activity of NEP in hippocampus. Ad-
ministration of valproic acid has also restored NEP activity
and memory deficit in adult rats caused by prenatal hyp-
oxia [20]. Valproic acid is a histone deacetylase (HDAC)
inhibitor. Correction of AD mice behavior deficit by val-
proic acid implies involvement of epigenetics in AD
pathogenesis. The clinical data of the effects of valproic
acid and other HDAC inhibitors on AD patients are still
needed. Estrogen and green tea all could increase NEP ac-
tivity and suggest their potential in AD treatment but
there is a long way before their final clinical application. In
vitro study of neuroectodermally converted mesenchymal
stem cells reported significant upregulation of NEP activ-
ity, while clinical translation of stem cell therapy still faces
many obstacles as reported.
Apolipoprotein E (ApoE) promotes Aβ clearance
Recent studies have indicated that it was the decreased
clearance/degradation rather than increased production
of Aβ account for its deposition in sporadic AD [21,22].
Possession of apolipoprotein E (ApoE) 4 allele increased
the risk of late onset sporadic AD, but the detailed
mechanisms are still unknown. Through nuclear recep-
tor stimulation, ApoE lipidation is increased. The lipi-
dated ApoE activates microglia and/or astrocyte to
degrade Aβ. It decreased brain amyloid plaque burden
and improved behavior functions in AD transgenic mice
[23,24]. In addition, the effect of ApoE on Aβ clearance
is also ApoE isoform-dependent: with ApoE2 the stron-
gest effect and ApoE4 was significantly less effective in
promoting Aβ clearance. The nuclear receptor-mediated,
ApoE-directed therapeutics thus can decrease brain Aβ
level and have disease-modifying potentials in AD pre-
vention [24]. Bexarotene is a nuclear receptor modulator
and ApoE activator, whether it is effective in AD preven-
tion needs to be explored clinically [25,26].
Drugs influencing Aβ blood–brain barrier transport
The receptor for advanced glycation end products (RAGE)
resides in the blood vessel wall cells and transport Aβ
across the blood brain barrier from systemic circulation to
facilitate their accumulation in brain. In contrast to
RAGE, low-density lipoprotein receptor-related protein-1
(LRP-1) mediates transport of Aβ peptide out of brain. In
AD patients the RAGE is elevated while the LRP-1 is lo-
wered. Inhibition of RAGE-ligand interaction suppresses
accumulation of Aβ in brain parenchyma in a mouse
transgenic model. Thus inhibition of RAGE and/or activa-
tion of LRP-1 may be a therapeutic target for AD, but
there are no clinical data available at present.
Drugs development based on the metals hypothesis
There is increasing evidence that metal (mainly Cu, Zn and
Fe) metabolism is involved in the major phthophysiological
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tion. Several chelators of Zn/Cu have been shown to inhibit
Aβ aggregation in vitro and in vivo. A phase II clinical trial
with clioquinol, a metal-protein-attenuating compound that
inhibits zinc and copper ions from binding to Aβ, led to
improved cognitive function, decreased plasma Aβ42 level
and zinc concentration as compared with control group.
Other metal chelators including XH1, DP-109, PBT2 and
so on showed improved cognitive function and decreased
CSF Aβ42 compared with placebo, but not plasma Aβ.
PBT2 was an orally bioavailable, second generation 8-OH
quinoline derivative of clioquinol, and is advancing as a
disease-modifying candidate drug for Alzheimer’s disease.
HMG-CoA reductase inhibitors (the “statins”)
Epidemiologic studies indicated reduced AD prevalence in
individuals who take statins. In vitro studies showed that
cholesterol-rich diet increased β-secretase processing of
APP while cholesterol lowering resulted in decreased Aβ
production. The view that increased levels of cholesterol
facilitate Aβ production while statins treatment lowers Aβ
production led to the hypothesis that statins may be a
promising treatment for AD. Clinical trial with atorvasta-
tin for 1 year provides some clinical benefit in AD
patients. Treatment with lovastatin resulted in decreased
plasma Aβ level. But still other studies did not observe the
decreased plasma Aβ levels. It is difficult to explain the in-
consistency between these studies; it may be related with
the different cognitive test used, treatment period, experi-
ment design, the discrepancy between studies, and also,
different stages of the disease respond to statins differ-
ently. Another important factor has to be addressed here
is that the dosage of statins used in clinical trial may be far
too less than that used in in vitro culture and conse-
quently, more different results in human trials than in
in vitro experiment. Although the effect of statins on Aβ
production is uncertain, the connection between choles-
terol and AD is still supported by many studies. Thus,
there is a need for larger clinical studies where both chol-
esterol metabolism and APP metabolism are followed dur-
ing and after treatment.
Monoamine oxidase inhibitors
MAO inhibitor deprenyl is an anti-Parkinson drug used
to inhibit dopamine degradation in the brain. Also as a
neuroprotective agent, deprenyl has been used to slow
the progress of neurodegenerative diseases such as AD
for many years. Although controversial, some clinical
trials have indicated that deprenyl could alleviate some
symptoms of AD. The in vitro experiment that depre-
nyl can regulate APP processing through PKC and
mitogen activated protein kinase (MAPK) signaling
pathways may explain its clinical effect in the late
stage of the disease. Another MAO-B inhibitorrasagiline is a bifunctional molecule which also has
acetylcholinesterase inhibition activity. Concerning its
neuroprotective mechanisms, including regulation of
APP processing, activation of PKC and MAPK signal-
ing pathways, inhibition of cell death markers and
upregulation of neurotrophic factors rationalize its ap-
plication to AD treatment, but the clinical trial data is
unpublished yet. Ladostigil is a dual acetylcholine-
butyrylcholineesterase and brain selective MAO-A and
-B inhibitor in vivo which was shown to antagonize
scopolamine-induced impairment in spatial memory. It
could also regulate APP processing, activate PKC and
MAPK. Inhibition of neuronal death markers, preven-
tion of the fall in mitochondrial membrane potential
and upregulation of neurotrophic factors and antioxi-
dative activity rationalize it as an anti-AD agent [27].
Still other compounds that inhibit MAO are also
under investigation for AD prevention [28].
Treatments based on tau pathology
Tau is a microtubule-associated protein normally present
in neurons. In AD, hyperphosphorylated tau forms the
paired helical filaments (PHF). This process severely
impairs axonal transport. A number of tau-focused tar-
gets for treatment of tauopathies such as AD, are
emerging following the recent development of trans-
genic animal models expressing tau abnormalities and
hyperphosphorylation.
Prevention of phosphorylation of tau
Tau phosphorylation increases dramatically in AD, sug-
gesting tau kinase inhibitors could be used as an anti-
AD treatment. Phosphorylation of tau is controlled by
different kinases and phosphatases. The activity of pro-
tein phosphatase (PP)-2A may increase dephosphoryla-
tion of tau. PP-2A also inhibits kinases such as MAPK,
which phosphorylate tau. Cyclin-dependent kinase-5
(CDK5) is a kinase suggested to phosphorylate tau in
AD. Transgenic mice in which CDK5 activity is activated
(by overexpression of the p25 activator) in adult brain
show evidence of a striking neurodegeneration with
some tau pathology. It has been reported that the con-
centration of p25 is elevated in the human AD brain.
Therefore, inhibition of CDK5 may suppress tau phos-
phorylation and prevent tangle formation. As report,
inhibitors of CDK5 appear to have some influence on
the development of pathology in some tau transgenic
mice [29]. There are as yet no reports of the use of
CDK5 inhibitors in humans.
Glycogen synthase kinase (GSK)-3β has also been sug-
gested as a drug target to inhibit tangle formation. It is
well established that this kinase can phosphorylate tau
in cells in culture and in the brains of transgenic mice.
This kinase is blocked by lithium, which has a long
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pressive therapy; it inhibits tau phosphorylation with
beneficial effects in animal models [30]. It has been
reported that lithium could be used for AD prevention,
particularly in individuals at risk of presenile FAD, which
has early onset [31]. The M1 muscarinic agonist AF267B
(also referred to as NGX267) has been shown to inhibit
GSK-3β activity and reduce tau pathology in transgenic
mice. Two additional inhibitors of tau hyperphosphory-
lation that have shown modest effect in transgenic
mouse models are propentofylline (PPF) and SRN-003-
556. Although the exact mechanism of PPF is unknown,
it reduced the active form of GSK-3β and prevented the
hyperphosphorylation of tau. SRN-003-556 was able to
reduce soluble tau that was hyperphosphorylated; how-
ever, no change was evidenced in existing neurofibrillary
tangles [32].
Finally, activated MAPK has been reported to be asso-
ciated with neurofibrillary tangles (NFTs) in human AD
[33]. A rather nonspecific inhibitor of this kinase was
used in tau transgenic mice, with apparently some bene-
ficial results [33]. But as with GSK3 and CDK5, there
are concerns that the multifaceted role of this kinase in
cellular metabolism would appear to lower the probabil-
ity that such inhibitors will make it into human studies.
Prevention of the aggregation of tau
Tau is ordinarily a soluble protein, but forms insoluble,
filamentous aggregates in the course of NFTs formation.
The mechanisms responsible for the conversion of a
normally soluble monomeric protein into the insoluble
filamentous aggregates have been the subject of intense
study and the target for some drug development. Other
approaches to tau include blocking its aggregation, ei-
ther directly or by inhibiting its proteolysis. Inhibitors of
tau aggregation independent of phosphorylation have
been found and tested in cell cultures [34]. Recent stud-
ies using cell models have demonstrated that certain
drug inhibitors are able to prevent tau protein aggregation
and even dissolve the developed aggregates, which include
phenothiazines, anthraquinones, polyphenols, thiacarbo-
cyanine dyes, N-phenylamines, thiazolyl-hydrazides, rho-
danines, quinoxalines, aminothienopyridazines and so on
[35]. Although these initial findings are promising, studies
in vivo are still needed to demonstrate efficacy and safety
of tau aggregate inhibitors.
Prevent the misfolding of tau
In addition to tau aggregation, the misfolding of hyper-
phosphorylated tau proteins has also been suggested to
contribute to the pathology of AD. Certain proteins are
able to regulate and prevent improper folding of tau in
order to avoid aggregation. The results from a study by
Dou and colleagues [36] suggested that increasing theactivation of molecular chaperones might prevent the
misfolding of tau, which would then reduce the develop-
ment of NFTs. Heat shock proteins have been shown to
activate chaperones that prevent misfolding and even
promote tau binding with microtubules [37]. Additional
research is required to determine whether targeting tau
chaperones would be able to produce significant benefit
in humans.
Tau immunotherapy
Over the past several years, there has been a growing
interest in immunotherapies targeted at reducing tau
levels as a strategy for treating AD. One of the possible
immunotherapeutic approaches being considered is the
selective reduction of pathological forms of tau. Asuni
and colleagues demonstrated that immunization of mice
expressing P301L-tau (JNPL3 mice) with a small
phospho-tau peptide (amino acids 379–408 with S396/
S404 phosphorylated) resulted in the production of anti-
bodies that entered the brain, which reduced the extent
and slowed the progression of the behavioural pheno-
type [38]. This group recently extended these studies by
creating a new mouse model with accelerated develop-
ment of tau pathology and immunizing with the same
phospho-tau peptide. Using this model they demon-
strated that immunization with this tau peptide resulted
in a reduction in soluble and insoluble tau phosphory-
lated at S396/S404 and a significant attenuation of cog-
nitive impairment [39]. Kayed R reported similar results
when phosphorylated tau antigens were used with
Freund’s-adjuvant (CFA) or with pertussis-toxin (PT)
and found 40% reduction in NFTs, reversal in neuro-
logical deficits and 20% increase in microglia in mice
[40]. A study from another group also demonstrated that
immunization of other tauopathy mouse models with
phospho-tau peptides also reduced tau pathology with-
out significant side effects [41]. Given this finding, it
would seem that a passive immunization protocol may
be a better therapeutic approach.
N-methyl-D-aspartate receptor (NMDA) antagonist
Glutamate is found in the neural pathways associated
with learning and memory. Abnormal levels of glutam-
ate may be responsible for neuronal cell dysfunction and
the eventual cell death and subsequent cognitive impair-
ment observed in AD. Age-related changes in NMDA
receptors have been found in cortical areas and in the
hippocampus in many species. In 2003, the FDA approved
memantine (Namenda; Forest Laboratories, New York,
NY), a low to moderate-affinity noncompetitive NMDA
receptor antagonist, for the treatment of moderate to se-
vere AD. Memantine appears to restore the function of
damaged nerve cells and reduce abnormal excitatory sig-
nals by the modulation of the NMDA receptor activity. It
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abnormal transmission of the neurotransmitter glutamate,
while allowing for the physiological transmission asso-
ciated with normal cell functioning [42]. In patients with
moderate to severe AD receiving a stable dose of donepe-
zil, the addition of memantine results in significant im-
provement in cognitive, functional, and global outcomes
compared with placebo [43]. Benefit was also shown with
memantine monotherapy in an outpatient study. How-
ever, in comparison, greater cognitive and functional im-
provement was seen in recipients of dual therapy.
Non-steroidal anti-inflammatory drugs (NSAIDs)
Microglial cells, closely related to the macrophage series
of cells in the periphery, increase in size and number in
the brain with AD. From this observation and the pres-
ence of complement in amyloid plaques, the concept of
AD as an inflammatory disease has emerged. More than
20 epidemiological studies, some with a follow-up design
and a good estimation of NSAIDs use via prescription
data from pharmacies have suggested that the prolonged
intake of NSAIDs may be associated with a reduced inci-
dence of AD [44]. In a Canadian 10-year population-
based cohort study, with the incidence of CIND (mild
cognitive impairment or cognitive impairment, not de-
mentia), AD, and all-cause dementia, it was shown that
there is an association between NSAID use and a lower
incidence of AD [45]. However clinical trials with potent
NSAIDs (indometacin) led to high withdrawal rates as
a result of gastrointestinal toxicity. Some trials with
COX-2 selective (celecoxib and rofecoxib) or unselective
(naproxen) NSAIDs or other anti-inflammatory drugs
such as dapsone, hydroxychloroquine and prednisone
have not shown a beneficial effect. Further trials with
NSAIDs shown that NSAIDs have an adverse effect in
later stages of AD pathogenesis, whereas asymptomatic
individuals treated with conventional NSAIDs such as
naproxen experience reduced AD incidence, but only
after 2 to 3 years. Thus, treatment effects differ at various
stages of disease.
Estrogens
Estrogens are neuroprotective against oxidative stress,
excitatory neurotoxicity, and ischemia in the brain. Studis
shown that estradiol administration significantly amelio-
rates the neurodegeneration characteristic of AD in ex-
perimental rat model. This may be attributed to its
powerful antioxidant, antiapoptotic, neurotrophic as well
as its antiamyloidogenic activities. Merlo et al. reported
that estrogen can activate matrix metalloproteinases-2
and −9 to increase beta amyloid degradation [46].
Receptors within the forebrain are found on the same
neurons as cholinergic receptors specifically affected by
the pathologic changes in AD. It is speculated that thewithdrawal of estrogen in postmenopausal women
results in a predisposition to AD. The use of estrogen
during hormone-replacement therapy (HRT) has also
been posited as a neuroprotective treatment for AD.
Several small short-term randomized clinical trials and
some epidemiologic studies [47] have suggested efficacy
of hormone therapy in the treatment of mild to moder-
ate AD. Results of a randomized controlled trial short-
term hormone therapy with transdermal estradiol
improved cognition for postmenopausal women with
AD [48]. However, a study by Shumaker and colleagues
indicated that postmenopausal women treated with es-
trogen plus progestin had an increased risk for dementia
[49]. Thus, there is insufficient evidence to support use
of HRT for prevention of AD and studies in AD with
oestrogens (e.g.premarin, raloxifen) are now mostly in
phase II.
Nicotine
Nicotine is a cholinergic agonist that acts both post-
synaptically and pre-synaptically to release acetylcholine,
which is an alkaloid derived from the leaves of tobacco
plants (Nicotiana tabacum and Nicotiana rustica). Nico-
tinic receptor densities are further attenuated in age-
associated neurodegenerative disorders in the elderly,
such as AD [50]. Numerous investigations, both in vivo
and in vitro, indicate that nicotine can enhance neurone
survival in response to a range of neurotoxic insults. Re-
cent report that nicotine evoked improvement in learn-
ing and memory is mediated through neuropeptide Y Y1
receptors in rat model of AD [51]. Published studies in
humans have reported the effects of intravenous or sub-
cutaneous nicotine administration on people with AD.
Significant improvements were reported in several cog-
nitive tasks such as free recall, visual attention and per-
ception and in mood although not on memory. There is
also the possibility that nicotine might have a preventive
action on AD, delaying the onset of clinical dementia by
reducing the rate of neuronal loss or mitigating its func-
tional consequences. There is also evidence that chronic
nicotine in vivo and tobacco use is capable in reducing
brain Aβ in elderly individuals although both the
mechanisms of action remain uncertain [52]. These
results suggest that central nicotinic cholinergic stimula-
tion deserves further investigation as a possible treat-
ment for AD. On the other hand, because nicotine has
been related with adverse effects, especially concerning
cardiovascular risks in elderly people, and also on sleep
and behaviour it is important to further study the effi-
cacy and safety of nicotine in patients with AD.
Melatonin
Melatonin (N-acetyl-5-methoxytryptamine) is a trypto-
phan metabolite, synthesized mainly by the pineal gland.
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cluding regulating circadian rhythms, clearing free radi-
cals, improving immunity, and generally inhibiting the
oxidation of biomolecules. Melatonin receptors appear
to be important in mechanisms of learning and memory
in mice, and it can alter electrophysiological processes
associated with memory, such as LTP. It is generally
accepted that melatonin deficit is closely related to aging
and age-related diseases. Decreased levels of melatonin
in serum and in CSF and the loss of melatonin diurnal
rhythm are observed in patients with AD [53]. The first
published evidence that melatonin may be useful in AD
was the demonstration that this neurohormone prevents
neuronal death caused by exposure to the amyloid beta
protein [54]. Melatonin also inhibits the aggregation of
the amyloid beta protein into neurotoxic microaggre-
gates. Recent report has indicated that melatonin can
alter lipid levels of mitochondrial membranes induced
by amyloid beta protein [55]. Melatonin has been shown
to prevent the hyperphosphorylation of the tau protein
in rats. Studies in rats suggest that melatonin may be ef-
fective for treating AD [56]. In AD patients, melatonin
supplementation has been suggested to improve circa-
dian rhythmicity, and to produce beneficial effects on
memory. Extensive clinical trials and studies with trans-
genic models are necessary to confirm the role of mela-
tonin at the late pathological stage of AD.
Cell transplantation and gene therapy
The degeneration of the cholinergic neurons in the nu-
cleus basalis of Meynert leads to a reduction in the cho-
linergic innervation in the cortical and subcortical
regions. This reduced neurotransmitter transduction
correlates with the clinical and pathological severity of
AD and is also a target for treatment. In AD rat model,
transplantation of cholinergic-rich tissue or peripheral
cholinergic neurons ameliorates abnormal behavior and
cognitive function. But no clinical trials in AD patients
have been initiated with this method. Lack of endogen-
ous nerve growth factor (NGF) can lead to memory defi-
cits, whereas NGF administration rescues neurons from
injury-induced cell damage and leads to associated
memory improvements [57] and thus NGF is good for
gene therapy. In a phase I trial of ex vivo NGF gene
delivery in eight individuals with mild AD [58], fibro-
blasts genetically modified to express human NGF were
transplanted into the forebrain. After mean follow-up
of 22 months in six subjects, no long-term adverse
effects of NGF occurred. PET studies showed a wide-
spread increase in glucose uptake by cortical neurons
after 6~8 months. The cognitive decline was improved
as evidenced by the mini-mental status examination
(MMSE) and AD Assessment scale. Brain autopsy from
one subject suggested robust growth responses to NGF.Although this is a small group and an open-label study
with no placebo control, these results are very encour-
aging. And additional clinical trials of NGF for AD are
warranted. Besides NGF, another candidate for gene ther-
apy is Aβ-degrading enzymes and the animal experi-
ments are also positive and the clinical trials are not
being initiated yet.
Other pharmacological therapies in clinical AD
trails
docosa-hexaenoic acid (DHA)
Epidemiological studies suggest that increased intake of
the omega-3(n-3) polyunsaturated fatty acid DHA is
associated with a reduced risk for AD [59]. DHA is the
most abundant omega 3 fatty acid in the brain. Data
from animal models support the hypothesis that DHA
maybe an effective treatment for AD by means of anti-
amyloid, antioxidant, and neuroprotective mechanisms
[60]. Administration of omega-3 fatty acid for 12 months
in a RCT with 204 patients with mild to moderate AD
showed no delay in the rate of cognitive decline accord-
ing to the MMSE or the cognitive portion of the AD As-
sessment scale. However, positive effects were observed
in a small group of patients with very mild AD [61].
Clioquinol
Metal chelation using clioquinol has been reported in a
pilot study with 36 patients with AD to reduce the rate of
cognitive loss in a double-blind, placebo-controlled, phase
2 clinical trial [62]. Clioquinol’s effect in this preliminary
study is due to its ability to chelate zinc and copper
associated with amyloid plaques. The mobilization and
removal of brain amyloid is believed to be basis of its
therapeutic effect. It was reported that clioquinol can
reduce zinc accumulation in neuritic plaques and inhibit
the amyloidogenic pathway in APP/PS1 transgenic mouse
brain [63].
Resveratrol
Resveratrol, a red wine polyphenol, is known to protect
against cardiovascular diseases and cancers, as well as to
promote anti-aging effects in numerous organisms. Some
recent studies on red wine bioactive compounds suggest
that resveratrol modulates multiple mechanisms of AD
pathology. It has been recently suggested that resveratrol
can be effective in slowing down AD development. As
reported in many biochemical studies, resveratrol seems
to exert its neuroprotective role through inhibition of Aβ
aggregation, by scavenging oxidants and exerting anti-
inflammatory activities [64]. In another paper, it demon-
strates that resveratrol is cytoprotective in human
neuroblastoma cells exposed to Aβ and or to Aβ-metal
complex mainly via its scavenging properties [65]. Resver-
atrol appears to mimic the effects of calorie restriction
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[66]. Cardioprotection, chemoprotection against cancers,
and anti-aging benefits all seem to be mediated through
resveratrol and CR-induced activation of sirtuin and other
proteins. Protection against Aβ toxicity in AD brains is
also modulated by sirtuins. The efficacy of resveratrol in
treating AD pathology depends on the extent to which
resveratrol metabolites become bioavailable and influence
both sirtuin-dependent and -independent signaling path-
ways in humans, and also depends on the next generation
of clinical testing and research that will need to study the
effects of resveratrol on a large number of human
subjects.
Conclusions
The pathogenesis of AD is a complex process involving
both genetic and environmental factors; therefore devel-
opment of effective disease-modifying drugs is proving
to be a difficult task. Current therapies for patients with
AD may ease symptoms by providing temporary im-
provement and reducing the rate of cognitive decline.
Given the wide array of available molecular targets and
the rapid progress toward identifying potential thera-
peutic compounds, the development of interventions
that substantially delay the onset or modify the progres-
sion of AD can be anticipated.
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